Neurological rehabilitation therapists specialize in helping individuals recover and adapt to life following neurological events or injuries, such as strokes, traumatic brain injuries, and spinal cord injuries. They use a combination of physical therapy, occupational therapy, and speech-language therapy to assist patients in regaining motor function, cognitive skills, and communication abilities. These specialists design individualized rehabilitation programs that focus on improving functional independence and promoting neuroplasticity—the brain's ability to reorganize and form new neural connections after injury. They work closely with other healthcare professionals, including neurologists, neurosurgeons, and neuropsychologists, to ensure comprehensive care and monitor progress throughout the rehabilitation process. Neurological rehabilitation therapists also educate patients and their families on coping strategies, assistive devices, and long-term management of neurological conditions. Their role extends to providing emotional and psychological support, addressing the challenges that patients face in adjusting to life after a neurological event. As advancements in rehabilitation techniques continue, these therapists incorporate new technologies such as virtual reality and robotic-assisted therapy to enhance recovery outcomes and accelerate functional gains.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States